Article
p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?
Carcinogenesis - 1 Jan 2007
Levesque Aime A, Eastman Alan
Abstract excerpt
The tumor suppressor protein p53 plays a pivotal role in the DNA damage response and is defective in >50% of human tumors, which has generated substantial interest in developing p53-targeted cancer therapies. Various therapeutic rationales targeting p53 are currently under investigation including attempts to both activate and inhibit p53. Elevation of p53 can be achieved by either reintroducing an exogenous p53...
Topics
Join the communities discussing this publication.